News
Nature Biotechnology 25, 150 - 151 (2007)
Published online: 1 February 2007 | doi:10.1038/nbt0207-150
Democrats prioritize pricing, generics and drug safety
Jeffrey L Fox1
- Washington
Abstract
The Democrats' new majority in the US Congress is already affecting biotechnology-related policies and programs.
